Chek the Channels
gammaCore Received Clearance for Prevention of Migraine
electrocore Inc is a commercial-stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Its product gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Label expansion of gammaCore. electroCore announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the label indication of gammaCore therapy to prevention of migraine in adult patients.
The largest market among approved indications. gammaCore is now approved for the prevention and treatment of migraines and cluster headache in adults. We think this is a significant milestone for the company. Prevention of migraine represents the largest growth opportunity for gammaCore sales. Estimates indicate that migraine sales will grow to $6.5 billion by 2027, potentially tripling in size. The migraine prophylaxis market could nearly quadruple to...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.